Nipruss (Sodium Nitroprusside Dihydrate)

Sodium nitroprusside, the active ingredient in Nipruss, is a vasodilator presented as an intravenous solution for intravenous use. It is employed to rapidly lower blood pressure in hypertensive emergencies, to provide controlled hypotension during surgical procedures, and to improve haemodynamics in acute heart failure patients.

GNH USA supplies Nipruss as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Sodium nitroprusside is a potent vasodilator used in critical care and operative settings.

Hypertensive emergencies: rapid and controlled reduction of severe arterial pressure. Controlled hypotension during surgery: maintain target low blood pressure to reduce bleeding. Acute heart failure: decrease preload and afterload to improve cardiac output.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Hypotension - Reflex tachycardia - Headache - Nausea - Flushing - Dizziness

Serious or Rare Side Effects: - Cyanide toxicity - Methemoglobinemia - Severe hypotension requiring intervention - Cardiac arrhythmias - Renal impairment - Pulmonary edema

Safe use of sodium nitroprusside requires careful monitoring and specific safeguards. - Continuous blood pressure monitoring: adjust infusion to avoid excessive hypotension. - Cyanide level assessment: consider during prolonged infusions or high doses. - Dose adjustment in renal or hepatic impairment: reduced clearance may increase toxicity risk. - Pregnancy and lactation: use only if benefits outweigh potential unknown risks. - Known hypersensitivity: discontinue immediately if allergic reaction occurs. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Sodium nitroprusside can interact with other agents that affect vascular tone or cyanide metabolism.

Major Interactions (Avoid): - Concurrent potent vasodilators (e.g., nitroglycerin, hydralazine): risk of profound hypotension. - Sodium thiosulfate or other cyanide‑binding agents administered simultaneously: may alter nitroprusside metabolism.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: additive blood pressure lowering effect. - Diuretics: may enhance volume depletion and hypotension. - Beta‑blockers: may mask reflex tachycardia. - Inhalational anesthetics: synergistic vasodilatory action. - Lithium: possible increase in lithium levels due to renal effects.